Siemens Healthineers Atellica IM High-Sensitivity Troponin I (TnIH) can be used to aid in offering rapid and accurate detection of AMI helping lead to a faster diagnosisA and now also assists clinicians to help identify future cardiovascular events and death based on the new prognostic risk claim extension.
>7 M
Over 7 million people present annually to Emergency Departments in the US with a chief complaint of chest pain1
1 in 10 patients
that present with chest pain are diagnosed with AMI2
$18.3B
Estimated annual US healthcare cost of myocardial infarction3
Supporting patients along the cardiac care continuum
This clinical brief examines how Atellica IM TnIH, the first and only high-sensitivity troponin assay in the U.S. to support a prognosis claim, supports clinical decision-making in the ED and ongoing patient management.
Key Insights
- Helps identify higher-risk patients to inform clinical judgment and support long-term cardiac care.
- A high-sensitivity assay that offers a 10-minute turnaround time.
- The first cardiac troponin assay in the U.S. to achieve both diagnostic and prognostic claims.